ibuprofen has been researched along with Gastric Ulcer in 91 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 9.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| "This double-blind, multicentre, placebo-controlled, parallel-group study compared the incidence of gastroduodenal ulcers associated with valdecoxib 10 mg daily (q." | 9.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| "The cumulative incidence of gastroduodenal ulcers >/=3 mm with rofecoxib (25 or 50 mg once daily) was significantly (P < 0." | 9.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 8.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| "Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications." | 7.79 | Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013) |
| "Limited data to date indicate that ibuprofen, when used in large doses to treat the pulmonary manifestations of cystic fibrosis, is relatively safe." | 7.70 | Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. ( Bell, EA; Foote, JM; Grothe, R; Wellendorf, J; Zivkovich, V, 1999) |
| "Most patients (65%) finished the trial, with 76% contributing data at 6 months, and 21% withdrew due to adverse effects." | 6.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 6.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| "Dimethylglycine did not produce any significant change in acid secretion, unlike famotidine." | 5.31 | Effect of dimethylglycine on gastric ulcers in rats. ( Hariganesh, K; Prathiba, J, 2000) |
| "In the pivotal efficacy and safety trials, discontinuation rates due to any cause and dyspepsia were significantly lower for the ibuprofen/famotidine combination versus ibuprofen alone." | 5.20 | One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 5.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| "Patients with osteoarthritis (age, >or=50 y) were randomized to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times daily for 12 months." | 5.12 | Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. ( Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM, 2007) |
| "Osteoarthritis patients > or =50 years of age without ulcers or erosive esophagitis at baseline endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combined with aspirin 81 mg/day, or ibuprofen 800 mg 3 times a day." | 5.11 | Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. ( Laine, L; Maller, ES; Quan, H; Simon, T; Yu, C, 2004) |
| "This double-blind, multicentre, placebo-controlled, parallel-group study compared the incidence of gastroduodenal ulcers associated with valdecoxib 10 mg daily (q." | 5.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| "We analysed pooled data from two identical double-blind, randomized, 12-week endoscopy studies which compared the gastroduodenal toxicity of placebo (n=371), rofecoxib 25 mg (n=390), rofecoxib 50 mg (n=379), and ibuprofen 2400 mg daily (n=376) in patients with osteoarthritis." | 5.09 | Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. ( Bolognese, JA; Harper, SE; Hawkey, CJ; Laine, L; Mortensen, E; Quan, HU, 2001) |
| "The cumulative incidence of gastroduodenal ulcers >/=3 mm with rofecoxib (25 or 50 mg once daily) was significantly (P < 0." | 5.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 4.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| " The diagnoses made by the community pharmacists from the pseudo-patients complaints were compared with the expected diagnosis of uncomplicated gastric ulcer caused by the use of ibuprofen." | 3.91 | Management of uncomplicated gastric ulcer in community pharmacy: a pseudo-patient study. ( Adelakun, AR; Showande, SJ, 2019) |
| "Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications." | 3.79 | Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013) |
| "The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers." | 3.77 | A fixed-dose combination ibuprofen and famotidine (Duexis). ( , 2011) |
| " Acute gastric ulceration in rats was produced by oral administration of ethanol and ibuprofen." | 3.74 | Antiulcerogenic activity of bark extract of Tabebuia avellanedae, Lorentz ex Griseb. ( Baggio, CH; dos Santos, AC; dos Santos, EP; Freitas, CS; Marques, MC; Mayer, B; Otuki, MF; Pizzolatti, MG; Twardowschy, A; Zacarias, AA, 2008) |
| "Over a 6-month period, two patients presented to a community hospital emergency department with perforated gastric ulcers as the result of recreational misuse of over-the-counter ibuprofen-codeine preparations." | 3.74 | Nurofen Plus misuse: an emerging cause of perforated gastric ulcer. ( Dutch, MJ, 2008) |
| " In a chronic model, by acetic acid-induced gastric ulcers, COX-2 was expressed at 7 days and was also associated with PGE(2) increase." | 3.73 | COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. ( Alarcón de la Lastra, C; Bruseghini, L; Manuel Herrerias, J; Motilva, V; Sánchez-Fidalgo, S, 2005) |
| "The objective of the present study has been to advance knowledge of the gastric role played by the amino acid L-Arginine (L-Arg) in the evolution of a chronic gastric ulcer." | 3.73 | Administration of L-arginine reduces the delay of the healing process caused by ibuprofen. Implication of COX and growth factors expression. ( Bruseghini, L; Esteras, A; Illanes, M; Martín-Lacave, I; Motilva, V; Sánchez-Fidalgo, S, 2005) |
| "To elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, and ibuprofen, a nonselective cyclooxygenase inhibitor, on the evolution of acetic-acid-induced gastric ulcers in rats, evaluating growth factor expression, the angiogenic process, cell proliferation and cell apoptosis." | 3.72 | Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. ( Illanes, M; Martín-Lacave, I; Motilva, V; Sánchez-Fidalgo, S, 2004) |
| "Limited data to date indicate that ibuprofen, when used in large doses to treat the pulmonary manifestations of cystic fibrosis, is relatively safe." | 3.70 | Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. ( Bell, EA; Foote, JM; Grothe, R; Wellendorf, J; Zivkovich, V, 1999) |
| " In rat adjuvant arthritis, NS-398 showed a therapeutic effect comparable to that seen with loxoprofen but less than that seen with indomethacin and diclofenac." | 3.68 | NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. ( Arai, I; Futaki, N; Hamasaka, Y; Higuchi, S; Iizuka, H; Otomo, S; Yoshikawa, K, 1993) |
| "A 3-year-old Chow Chow was examined because of a 2-week history of vomiting and anorexia after administration of 200 mg of ibuprofen." | 3.68 | Gastric perforation associated with administration of ibuprofen in a dog. ( Fingland, RB; Godshalk, CP; Roush, JK; Sikkema, D; Vorhies, MW, 1992) |
| "Most patients (65%) finished the trial, with 76% contributing data at 6 months, and 21% withdrew due to adverse effects." | 2.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| " Each subject took, over four separate 10-day dosing periods, ibuprofen 400 mg t." | 2.69 | Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen. ( Courtauld, E; Donnelly, MT; Hawkey, CJ; Richardson, P; Stack, WA, 2000) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 2.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| "Ibuprofen is an inexpensive short-acting NSAID and is readily available in liquid formulation for administration to bottle-fed calves." | 1.43 | Adverse effects of a 10-day course of ibuprofen in Holstein calves. ( Anderson, M; Behrens, N; Carvallo Chaigneau, FR; Gershwin, LJ; Gunnarson, B; McEligot, H; Walsh, P, 2016) |
| " We present the case of a previously healthy 3-year-old boy who developed severe chronic gastric outlet obstruction and antral stenosis after a short-term ingestion of liquid ibuprofen at a dosage not thought to be associated with unfavorable effects." | 1.39 | Pneumatic pyloric dilatation for the treatment of gastric outlet obstruction in a child. ( Alvisi, P; Billi, P; Fascetti Leon, F; Gobbi, D; Lambertini, A; Lima, M, 2013) |
| " A small amount of carrier phospholipid significantly increases the rate and the extent of dissolution, which may increase the bioavailability of ibuprofen." | 1.38 | Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance. ( Brausch, JF; Hussain, MD; Saxena, V; Talukder, RM, 2012) |
| "In ibuprofen-treated rats, the lipid peroxidation measured as thiobarbituric acid reactive substances (TBARS), a marker for free radical-induced tissue damage, is also significantly decreased by taurine." | 1.32 | Taurine prevents Ibuprofen-induced gastric mucosal lesions and influences endogenous antioxidant status of stomach in rats. ( Balasubramanian, T; Felix, AJ; Somasundaram, M, 2004) |
| "Dimethylglycine did not produce any significant change in acid secretion, unlike famotidine." | 1.31 | Effect of dimethylglycine on gastric ulcers in rats. ( Hariganesh, K; Prathiba, J, 2000) |
| " Although this study failed to describe a dose-response relationship, it appears that there are significant breed differences in susceptibility to GIU subsequent to ibuprofen exposure." | 1.30 | A case-control study of acute ibuprofen toxicity in dogs. ( Hungerford, LL; Poortinga, EW, 1998) |
| " Following clinical observations that this drug combination induces significant adverse effects, its gastric toxicity was investigated in rats." | 1.28 | Potentiation of gastric toxicity of ibuprofen by paracetamol in the rat. ( Bhattacharya, SK; Goel, RK; Tandon, R, 1991) |
| "Acetaminophen has been proposed as an agent which protects the gastric mucosa against damage induced by aspirin and other non-steroidal anti-inflammatory agents." | 1.27 | Effect of acetaminophen on human gastric mucosal injury caused by ibuprofen. ( Lanza, FL; Nelson, RS; Rack, MF; Royer, GL; Schwartz, JH; Seckman, CE, 1986) |
| "Ibuprofen was observed to modulate some immunological phenomena with marked predominance of immunosuppressive component." | 1.27 | Selected pharmacological and immunopharmacological indices of ibuprofen. ( Giełdanowski, J, 1987) |
| "Butibufen was within the potency range of ibuprofen as an antipyretic and analgesic agent and greater than that of acetylsalicylic acid." | 1.26 | Some aspects of the pharmacology of butibufen, a non-steroidal anti-inflammatory agent. ( Aparicio, L, 1977) |
| " The degree of gastric or intestinal irritation seen with dosing of other drugs was as follows; indomethacin greater than diclofenac Na greater than ibuprofen greater than aspirin greater than phenylbutazone or indomethacin greater than CH-800 = diclofenac Na greater than ibuprofen greater than phenylbutazone, respectively." | 1.26 | [Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)]. ( Ohtsuki, H; Okabe, S; Tabata, K, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (10.99) | 18.7374 |
| 1990's | 14 (15.38) | 18.2507 |
| 2000's | 33 (36.26) | 29.6817 |
| 2010's | 32 (35.16) | 24.3611 |
| 2020's | 2 (2.20) | 2.80 |
| Authors | Studies |
|---|---|
| Hino, K | 1 |
| Nakamura, H | 1 |
| Nagai, Y | 1 |
| Uno, H | 1 |
| Nishimura, H | 1 |
| Velázquez, C | 1 |
| Praveen Rao, PN | 2 |
| Knaus, EE | 3 |
| Metwally, KA | 1 |
| Yaseen, SH | 1 |
| Lashine, el-SM | 1 |
| El-Fayomi, HM | 1 |
| El-Sadek, ME | 1 |
| Velázquez, CA | 2 |
| Citro, ML | 1 |
| Keefer, LK | 1 |
| Chatterjee, NR | 1 |
| Kulkarni, AA | 1 |
| Ghulekar, SP | 1 |
| Akhter, M | 1 |
| Husain, A | 1 |
| Azad, B | 1 |
| Ajmal, M | 1 |
| Huang, Z | 1 |
| Abdellatif, KR | 2 |
| Chowdhury, MA | 1 |
| Reisz, JA | 1 |
| DuMond, JF | 1 |
| King, SB | 1 |
| Hegazy, GH | 1 |
| Ali, HI | 1 |
| Redasani, VK | 1 |
| Bari, SB | 1 |
| Navarro, L | 1 |
| Rosell, G | 1 |
| Sánchez, S | 1 |
| Boixareu, N | 1 |
| Pors, K | 1 |
| Pouplana, R | 1 |
| Campanera, JM | 1 |
| Pujol, MD | 1 |
| Meijuan, Z | 1 |
| Yu, P | 1 |
| Yuan, J | 1 |
| Yu, T | 1 |
| Sun, D | 2 |
| Showande, SJ | 1 |
| Adelakun, AR | 1 |
| Panda, SS | 1 |
| Girgis, AS | 1 |
| Honkanadavar, HH | 1 |
| George, RF | 1 |
| Srour, AM | 1 |
| Yehiyan, A | 1 |
| Barman, S | 1 |
| Varia, H | 1 |
| Pettit, S | 1 |
| Kaur, A | 1 |
| Pathak, DP | 1 |
| Sharma, V | 1 |
| Narasimhan, B | 1 |
| Sharma, P | 1 |
| Mathur, R | 1 |
| Wakode, S | 1 |
| Kuan, R | 1 |
| Holt, RJ | 5 |
| Johnson, KE | 1 |
| Kent, JD | 6 |
| Peura, DA | 1 |
| Malone, D | 1 |
| Gobbi, D | 1 |
| Billi, P | 1 |
| Fascetti Leon, F | 1 |
| Alvisi, P | 1 |
| Lambertini, A | 1 |
| Lima, M | 1 |
| Deeks, ED | 1 |
| Tuskey, A | 1 |
| Peura, D | 1 |
| Fukushima, E | 1 |
| Monoi, N | 1 |
| Mikoshiba, S | 1 |
| Hirayama, Y | 1 |
| Serizawa, T | 1 |
| Adachi, K | 1 |
| Koide, M | 1 |
| Ohdera, M | 1 |
| Murakoshi, M | 1 |
| Kato, H | 1 |
| Bello, AE | 5 |
| Grahn, AY | 4 |
| Rice, P | 1 |
| Ball, J | 2 |
| Taha, AS | 2 |
| Shkair, AM | 1 |
| Shakya, AK | 1 |
| Raghavendra, NM | 1 |
| Naik, RR | 1 |
| Abdelgawad, MA | 1 |
| Elshemy, HA | 1 |
| Alsayed, SS | 1 |
| Walsh, P | 1 |
| Carvallo Chaigneau, FR | 1 |
| Anderson, M | 1 |
| Behrens, N | 1 |
| McEligot, H | 1 |
| Gunnarson, B | 1 |
| Gershwin, LJ | 1 |
| Liu, J | 1 |
| He, J | 1 |
| Yang, C | 1 |
| Hu, T | 1 |
| Zhang, L | 1 |
| Cao, H | 1 |
| Tong, AP | 1 |
| Song, X | 1 |
| Xie, Y | 1 |
| He, G | 1 |
| Guo, G | 1 |
| Luo, Y | 1 |
| Cheng, P | 1 |
| Zheng, Y | 1 |
| Lanza, FL | 3 |
| Marathi, UK | 1 |
| Anand, BS | 1 |
| Lichtenberger, LM | 1 |
| Twardowschy, A | 1 |
| Freitas, CS | 1 |
| Baggio, CH | 1 |
| Mayer, B | 1 |
| dos Santos, AC | 1 |
| Pizzolatti, MG | 1 |
| Zacarias, AA | 1 |
| dos Santos, EP | 1 |
| Otuki, MF | 1 |
| Marques, MC | 1 |
| Amir, M | 2 |
| Kumar, S | 1 |
| Girard, P | 1 |
| Coppé, MC | 1 |
| Pansart, Y | 1 |
| Gillardin, JM | 1 |
| Caunedo-Alvarez, A | 1 |
| Gómez-Rodríguez, BJ | 1 |
| Romero-Vázquez, J | 1 |
| Argüelles-Arias, F | 1 |
| Romero-Castro, R | 1 |
| García-Montes, JM | 1 |
| Pellicer-Bautista, FJ | 1 |
| Herrerías-Gutiérrez, JM | 1 |
| Saifullah, K | 1 |
| Akhter, W | 1 |
| Rasheed, A | 1 |
| Kumar, CK | 1 |
| Mishra, A | 1 |
| Raval, JP | 1 |
| Gandhi, AN | 1 |
| Akhaja, TN | 1 |
| Myangar, KN | 1 |
| Patel, NH | 1 |
| Hussain, MD | 1 |
| Saxena, V | 1 |
| Brausch, JF | 1 |
| Talukder, RM | 1 |
| Laine, L | 4 |
| Kivitz, AJ | 1 |
| Schiff, MH | 1 |
| Chan, FK | 1 |
| Uzgören-Baran, A | 1 |
| Tel, BC | 1 |
| Sarıgöl, D | 1 |
| Oztürk, Eİ | 1 |
| Kazkayası, I | 1 |
| Okay, G | 1 |
| Ertan, M | 1 |
| Tozkoparan, B | 1 |
| Chandiran, S | 1 |
| Vyas, S | 1 |
| Sharma, N | 1 |
| Sharma, M | 1 |
| Sikes, DH | 1 |
| Agrawal, NM | 1 |
| Zhao, WW | 1 |
| Recker, DP | 1 |
| Verburg, KM | 1 |
| Hunt, RH | 1 |
| Harper, S | 2 |
| Callegari, P | 1 |
| Yu, C | 2 |
| Quan, H | 4 |
| Evans, J | 1 |
| James, C | 1 |
| Bowen, B | 1 |
| Rashid, F | 1 |
| Cocco, MT | 1 |
| Congiu, C | 1 |
| Onnis, V | 1 |
| Morelli, M | 1 |
| Cauli, O | 1 |
| Shostak, NA | 1 |
| Riabkova, AA | 1 |
| Savel'ev, VS | 1 |
| Maliarova, LP | 1 |
| Makhlouf, AA | 1 |
| Maklad, YA | 1 |
| Sudheer Kumar, M | 1 |
| Sridhar Reddy, B | 1 |
| Kiran Babu, S | 1 |
| Bhilegaonkar, PM | 1 |
| Shirwaikar, A | 1 |
| Unnikrishnan, MK | 1 |
| Maller, ES | 1 |
| Simon, T | 2 |
| Summerton, N | 1 |
| Sánchez-Fidalgo, S | 3 |
| Martín-Lacave, I | 2 |
| Illanes, M | 2 |
| Motilva, V | 3 |
| Balasubramanian, T | 1 |
| Somasundaram, M | 1 |
| Felix, AJ | 1 |
| Alarcón de la Lastra, C | 1 |
| Bruseghini, L | 2 |
| Manuel Herrerias, J | 1 |
| Esteras, A | 1 |
| Narayan, S | 1 |
| Devi, RS | 1 |
| Srinivasan, P | 1 |
| Shyamala Devi, CS | 1 |
| Zhao, X | 1 |
| Tao, X | 1 |
| Wei, D | 1 |
| Song, Q | 1 |
| Gambero, A | 1 |
| Maróstica, M | 1 |
| Becker, TL | 1 |
| Pedrazzoli, J | 1 |
| Berezin, SH | 1 |
| Bostwick, HE | 1 |
| Halata, MS | 1 |
| Feerick, J | 1 |
| Newman, LJ | 1 |
| Medow, MS | 1 |
| Hawkey, CJ | 3 |
| Weinstein, WM | 1 |
| Smalley, W | 1 |
| Gitton, X | 1 |
| Sallstig, P | 1 |
| Stricker, K | 1 |
| Krammer, G | 1 |
| Mellein, B | 1 |
| Richard, D | 1 |
| Matchaba, P | 1 |
| Dutch, MJ | 1 |
| Diamantis, W | 1 |
| Melton, J | 1 |
| Sofia, RD | 1 |
| Ciofalo, VB | 1 |
| Parmar, NS | 1 |
| Ghosh, MN | 1 |
| Lems, WF | 1 |
| van Berge Henegouwen, GP | 1 |
| Bijlsma, JW | 1 |
| Wagner, KA | 1 |
| Nandi, J | 1 |
| King, RL | 1 |
| Levine, RA | 1 |
| Smith, KJ | 1 |
| Taylor, DH | 1 |
| Futaki, N | 1 |
| Yoshikawa, K | 1 |
| Hamasaka, Y | 1 |
| Arai, I | 1 |
| Higuchi, S | 1 |
| Iizuka, H | 1 |
| Otomo, S | 1 |
| Villar, D | 1 |
| Buck, WB | 1 |
| Gonzalez, JM | 1 |
| Poortinga, EW | 1 |
| Hungerford, LL | 1 |
| Rack, MF | 2 |
| Simon, TJ | 1 |
| Bolognese, JA | 2 |
| Hoover, ME | 1 |
| Wilson, FR | 1 |
| Harper, SE | 2 |
| Bell, EA | 1 |
| Grothe, R | 1 |
| Zivkovich, V | 1 |
| Foote, JM | 1 |
| Wellendorf, J | 1 |
| Bath, R | 1 |
| Johanson, J | 1 |
| Schwartz, H | 1 |
| Stern, S | 1 |
| Bolognese, J | 1 |
| Pfau, PR | 1 |
| Lichenstein, GR | 1 |
| Kaufman, DW | 1 |
| Kelly, JP | 1 |
| Wiholm, BE | 1 |
| Laszlo, A | 1 |
| Sheehan, JE | 1 |
| Koff, RS | 1 |
| Shapiro, S | 1 |
| Donnelly, MT | 1 |
| Richardson, P | 1 |
| Courtauld, E | 1 |
| Stack, WA | 1 |
| Andrade, A | 1 |
| Namora, SF | 1 |
| Woisky, RG | 1 |
| Wiezel, G | 1 |
| Najjar, R | 1 |
| Sertié, JA | 1 |
| de Oliveira Silva, D | 1 |
| Hariganesh, K | 1 |
| Prathiba, J | 1 |
| Bansal, AK | 2 |
| Khar, RK | 2 |
| Dubey, R | 2 |
| Sharma, AK | 2 |
| Quan, HU | 1 |
| Mortensen, E | 1 |
| Jüni, P | 1 |
| Rutjes, AW | 1 |
| Dieppe, PA | 1 |
| Tabata, K | 1 |
| Ohtsuki, H | 1 |
| Okabe, S | 1 |
| Aparicio, L | 1 |
| Godshalk, CP | 1 |
| Roush, JK | 1 |
| Fingland, RB | 1 |
| Sikkema, D | 1 |
| Vorhies, MW | 1 |
| Skriabin, ON | 1 |
| Baranchuk, VN | 1 |
| Manyshev, VG | 1 |
| Kurygin, AA | 1 |
| Bhattacharya, SK | 2 |
| Goel, RK | 1 |
| Tandon, R | 1 |
| Puscas, I | 1 |
| Hajdu, A | 1 |
| Buzás, G | 1 |
| Bernáth, Z | 1 |
| Somerville, K | 1 |
| Faulkner, G | 1 |
| Langman, M | 1 |
| Giełdanowski, J | 1 |
| Porkodi, R | 1 |
| Raghuram, K | 1 |
| Parthiban, M | 1 |
| Chandrasekaran, AN | 1 |
| Royer, GL | 1 |
| Nelson, RS | 1 |
| Seckman, CE | 1 |
| Schwartz, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment[NCT00984815] | Phase 3 | 86 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658] | Phase 3 | 627 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216] | Phase 3 | 906 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Single Arm, Open-label Pilot Trial Examining the Effects of Pau d' Arco on Primary Dysmenorrhea in Reproductive Age Women[NCT04245540] | Early Phase 1 | 12 participants (Actual) | Interventional | 2019-07-30 | Completed | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The non-pain symptom scale of the SODA questionnaire ranges from 7 - 35. Change from baseline compares the score at Week 54 to the baseline score for each participant that completed the non-pain symptom questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -1.44 |
The pain intensity scale of the SODA questionnaire ranges from 2 - 47. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the pain intensity questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -3.22 |
The satisfaction with dyspepsia-related health scale of the SODA questionnaire ranges from 2 - 23. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the Satisfaction questions of the SODA questionnaire at baseline and Week 54. A positive change from baseline in the SODA satisfaction scale represents a participant's overall improved satisfaction with their dyspepsia-related health. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | 2.69 |
(NCT00984815)
Timeframe: 54 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 76 |
The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 9 |
The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 37 |
| Ibuprofen | 34 |
The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 40 |
| Ibuprofen | 38 |
The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 0 |
| Ibuprofen | 0 |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 8 |
| Ibuprofen | 14 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 55 |
| Ibuprofen | 52 |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 63 |
| Ibuprofen | 61 |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks
| Intervention | particpants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 0 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
5 reviews available for ibuprofen and Gastric Ulcer
| Article | Year |
|---|---|
Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Interactions; Duodenal Ulcer; Famot | 2013 |
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; G | 2013 |
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Famot | 2014 |
['Stomach-friendly' NSAIDs: careful optimism?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Gastritis; Humans; Ibuprofen; Misopro | 1995 |
Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1998 |
14 trials available for ibuprofen and Gastric Ulcer
| Article | Year |
|---|---|
One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non- | 2008 |
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2012 |
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclo | 2002 |
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase | 2003 |
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2004 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclof | 2007 |
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenas | 1999 |
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Topics: Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D | 1999 |
Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Dose-Respo | 2000 |
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; | 2001 |
Prevention of non-steroidal anti-inflammatory agents induced acute gastric mucosal lesions by carbonic anhydrase inhibitors. An endoscopic study.
Topics: Acetazolamide; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Mucosa; Gastroscopy; | 1989 |
72 other studies available for ibuprofen and Gastric Ulcer
| Article | Year |
|---|---|
Nonsteroidal antiinflammatory agents. 2. [(Heteroarylamino)phenyl]alkanoic acids.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Carboxylic Acids; Carrageenan; Edema; Fe | 1983 |
Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azo Compounds; Cyclooxygenase 1; Cyclooxy | 2005 |
Non-carboxylic analogues of arylpropionic acids: synthesis, anti-inflammatory activity and ulcerogenic potential.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Flurbiprofen; Ibuprofen; Male; Naproxen; Propionat | 2007 |
O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cycloo | 2007 |
Synthesis, pharmacological activity and hydrolytic behavior of ethylenediamine and benzathine conjugates of ibuprofen.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dis | 2008 |
Aroylpropionic acid based 2,5-disubstituted-1,3,4-oxadiazoles: synthesis and their anti-inflammatory and analgesic activities.
Topics: Acute Disease; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclizatio | 2009 |
Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase Inhibitors; Edema; Est | 2011 |
Design, synthesis, biological evaluation, and comparative Cox1 and Cox2 docking of p-substituted benzylidenamino phenyl esters of ibuprofenic and mefenamic acids.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Drug Design; Edema; Ibupr | 2012 |
Synthesis and evaluation of mutual prodrugs of ibuprofen with menthol, thymol and eugenol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Eugenol; Female; Hydrogen-Ion | 2012 |
Synthesis and biological properties of aryl methyl sulfones.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Dimet | 2018 |
Stomach ulcer caused by mistakenly oral medication of 14,400 mg ibuprofen: A case report.
Topics: Adult; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylo | 2023 |
Management of uncomplicated gastric ulcer in community pharmacy: a pseudo-patient study.
Topics: Clinical Competence; Community Pharmacy Services; Cross-Sectional Studies; Diagnosis, Differential; | 2019 |
Synthesis of new ibuprofen hybrid conjugates as potential anti-inflammatory and analgesic agents.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygena | 2020 |
Short-course high-dose ibuprofen causing both early and delayed jejunal perforations in a non-smoking man.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Humans; Ibuprofen; Intestinal Pe | 2017 |
Synthesis, biological evaluation and docking study of N-(2-(3,4,5-trimethoxybenzyl)benzoxazole-5-yl) benzamide derivatives as selective COX-2 inhibitor and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Benzamides; Benzoxazoles; Carrageenan; Cycloox | 2018 |
Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Drug Combinations | 2013 |
Pneumatic pyloric dilatation for the treatment of gastric outlet obstruction in a child.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Combined Modality Therapy; Dilatation; Ga | 2013 |
Protective effects of acetaminophen on ibuprofen-induced gastric mucosal damage in rats with associated suppression of matrix metalloproteinase.
Topics: Acetaminophen; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Do | 2014 |
The ibuprofen-famotidine combined pill - a promise fulfilled.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspepsia; Famotidine; Female; Histamine H2 Antagonists; Hu | 2015 |
Molecular Modeling, Synthesis and Pharmacological Evaluation of 1,3,4- Thiadiazoles as Anti-inflammatory and Analgesic Agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cy | 2016 |
Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 I | 2016 |
Adverse effects of a 10-day course of ibuprofen in Holstein calves.
Topics: Abomasum; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blood Urea Nitrogen; C | 2016 |
Gastroprotective effects of several H2RAs on ibuprofen-induced gastric ulcer in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Gastric Mucosa; Histamine H2 Antagonists; Ibuprofe | 2016 |
Antiulcerogenic activity of bark extract of Tabebuia avellanedae, Lorentz ex Griseb.
Topics: Animals; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Ibupr | 2008 |
Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation properties of ibuprofen derivatives.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Female; Gastric Mu | 2007 |
Gastroprotective effect of Saccharomyces boulardii in a rat model of ibuprofen-induced gastric ulcer.
Topics: Animals; Body Weight; Cytoprotection; Disease Models, Animal; Gastric Mucosa; Ibuprofen; Male; Nitra | 2010 |
Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Cyclooxygenase 2 Inhibitors | 2010 |
Design, synthesis and pharmacological evaluation of novel azole derivatives of aryl acetic acid as anti-inflammatory and analgesic agents.
Topics: Acetates; Analgesics; Animals; Anti-Inflammatory Agents; Drug Design; Gastric Mucosa; Ibuprofen; Inf | 2011 |
Synthesis, hydrolysis studies and phamacodynamic profiles of amide prodrugs of dexibuprofen with amino acids.
Topics: Amides; Amino Acids; Analgesics; Animals; Anti-Inflammatory Agents; Chemical Phenomena; Feces; Human | 2011 |
Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation properties of new 2-(4-isobutylphenyl)propanoic acid derivatives.
Topics: Acute Disease; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Dise | 2012 |
A fixed-dose combination ibuprofen and famotidine (Duexis).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Duodenal Ulcer; F | 2011 |
Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance.
Topics: Administration, Oral; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemis | 2012 |
Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Huma | 2012 |
Thiazolo[3,2-b]-1,2,4-triazole-5(6H)-one substituted with ibuprofen: novel non-steroidal anti-inflammatory agents with favorable gastrointestinal tolerance.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dose-Response Relationshi | 2012 |
Synthesis and evaluation of antioxidant-s-(+)-Ibuprofen hybrids as gastro sparing NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Chromatography, High Pressure Liquid | 2013 |
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties.
Topics: Acetic Acid; Administration, Oral; Amides; Analgesics, Non-Narcotic; Animals; Ibuprofen; Injections, | 2003 |
[Gastrointestinal hemorrhages as complications of gastropathies associated with intake of nonsteroidal anti-inflammatory drugs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Duodenal Ulcer; Duodeno | 2003 |
Synthesis and analgesic-anti-inflammatory activities of some 1,2,4-triazine derivatives.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Ibuprofen; Indicators and Reag | 2004 |
Antiinflammatory and antiulcer activities of phytic acid in rats.
Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Cold Temperature; Ethanol; Famotidine; Gastric | 2004 |
Evidence in practice--number 3: Cox 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medic | 2004 |
Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Cyclooxygenase 2; C | 2004 |
Taurine prevents Ibuprofen-induced gastric mucosal lesions and influences endogenous antioxidant status of stomach in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Catalase; Female; Gastric Mucosa; Gl | 2004 |
COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions.
Topics: Acetic Acid; Acute Disease; Animals; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2005 |
Administration of L-arginine reduces the delay of the healing process caused by ibuprofen. Implication of COX and growth factors expression.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Chronic Disease; Cyclooxyge | 2005 |
Pterocarpus santalinus: a traditional herbal drug as a protectant against ibuprofen induced gastric ulcers.
Topics: Animals; Anti-Ulcer Agents; Cation Transport Proteins; Gastric Mucosa; Ibuprofen; Male; Phytotherapy | 2005 |
Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Edema; Female | 2006 |
Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytoprotection; D | 2007 |
Gastrointestinal bleeding in children following ingestion of low-dose ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Female; Gastritis; Gastrointestinal Hemor | 2007 |
Nurofen Plus misuse: an emerging cause of perforated gastric ulcer.
Topics: Abdominal Pain; Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Codeine; Drug Co | 2008 |
Comparative gastric ulcerogenic effects of meseclazone, 5-chlorosalicylic acid and other nonsteroidal anti-inflammatory drugs following acute and repeated oral administration to rats.
Topics: Animals; Anti-Inflammatory Agents; Benzoxazines; Biotransformation; Fenoprofen; Ibuprofen; Indometha | 1980 |
Gastric anti-ulcer activity of (+)-cyanidanol-3, a histidine decarboxylase inhibitor.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Benzopyrans; Carboxy-Lyases; Catechin; Female; Gastric Acidity | 1981 |
Effects of nonsteroidal antiinflammatory drugs on ulcerogenesis and gastric secretion in pylorus-ligated rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dinoprostone; Gastric Acid; Gastric Mucos | 1995 |
Another case of gastric perforation associated with administration of ibuprofen in a dog.
Topics: Animals; Dog Diseases; Dogs; Ibuprofen; Male; Peptic Ulcer Perforation; Stomach Ulcer | 1993 |
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygena | 1993 |
A case-control study of acute ibuprofen toxicity in dogs.
Topics: Acute Kidney Injury; Animals; Case-Control Studies; Dog Diseases; Dogs; Duodenal Ulcer; Female; Gast | 1998 |
Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Child; Cystic Fibrosis; Female; Humans; Ib | 1999 |
NSAIDs and alcohol: never the twain shall mix?
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase | 1999 |
The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption.
Topics: Acute Disease; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Contro | 1999 |
Synthesis and characterization of a diruthenium-ibuprofenato complex comparing its anti-inflammatory activity with that of a copper(II)-ibuprofenato complex.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Gastrointestinal Hemorrhage; I | 2000 |
Effect of dimethylglycine on gastric ulcers in rats.
Topics: Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Famotidine; Gastric Juice; Glutathione | 2000 |
Activity profile of glycolamide ester prodrugs of ibuprofen.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Esters; | 2001 |
Alkyl ester prodrugs for improved topical delivery of ibuprofen.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Edema; Ibuprofen; Prodrug | 2001 |
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase | 2002 |
[Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)].
Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents; Aspirin; Diclofenac; Digestive Sy | 1979 |
Some aspects of the pharmacology of butibufen, a non-steroidal anti-inflammatory agent.
Topics: Acetates; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Edema; Gr | 1977 |
Gastric perforation associated with administration of ibuprofen in a dog.
Topics: Animals; Anorexia; Dog Diseases; Dogs; Duodenostomy; Female; Gastrostomy; Ibuprofen; Peptic Ulcer Pe | 1992 |
[The results of the endoscopic diathermy coagulation of hemorrhaging gastroduodenal ulcers].
Topics: Acute Disease; Duodenal Ulcer; Electrocoagulation; Female; Hemostasis, Endoscopic; Humans; Ibuprofen | 1992 |
Potentiation of gastric toxicity of ibuprofen by paracetamol in the rat.
Topics: Acetaminophen; Administration, Oral; Animals; Drug Synergism; Gastric Mucosa; Ibuprofen; Male; Rats; | 1991 |
Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Duodenal Ulcer; Female; Humans; Ibuprofen; Indome | 1986 |
Selected pharmacological and immunopharmacological indices of ibuprofen.
Topics: Animals; Antibody-Producing Cells; Guinea Pigs; Humans; Ibuprofen; Immune System; In Vitro Technique | 1987 |
Therapeutic efficacy and gastric tolerance of ibuprofen (Brufen) at 1600-2400 mg dosage in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Gastric Mucosa; Humans; Ibuprofen; Male; Stomach Ulcer | 1987 |
Effect of acetaminophen on human gastric mucosal injury caused by ibuprofen.
Topics: Acetaminophen; Adult; Female; Gastric Mucosa; Humans; Ibuprofen; Male; Middle Aged; Stomach Ulcer; T | 1986 |